Skip to main content
. 2022 Aug 23;12(3):2731–2738. doi: 10.1002/cam4.5161

TABLE 4.

Adverse events

Any grade G3‐4 G1‐2
Hypertension 54 (44.6) 5 (4.1) 49 (40.5)
Thrombocytopenia 45 (37.2) 4 (3.3) 41 (33.9)
Fatigue 44 (36.4) 0 44 (36.4)
AST elevation 42 (34.7) 9 (7.4) 33 (27.3)
Proteinuria 35 (28.9) 5 (4.1) 30 (24.7)
Anemia 30 (24.8) 1 (0.8) 29 (24.0)
ALT elevation 24 (19.8) 3 (2.5) 21 (17.4)
Blood bilirubin increase 24 (19.8) 2 (1.6) 22 (18.2)
Nausea 24 (19.8) 1 (0.8) 23 (19.0)
Anorexia 23 (19.0) 0 23 (19.0)
Neutropenia 14 (11.6) 3 (2.5) 11 (9.1)
Rash 13 (10.7) 2 (1.7) 11 (9.1)
Pruritus 13 (10.7) 3 (0.8) 10 (8.2)
Gastrointestinal bleeding 6 (5.0) 4 (3.3) 2 (1.7)
Vomiting 6 (5.0) 0 6 (5.0)
Diarrhea 6 (5.0) 0 6 (5.0)
Gastrointestinal perforation 3 (2.5) 3 (2.5) 0
Hypothyroidism 1 (0.8) 0 1 (0.8)
Intracranial hemorrhage 1 (0.8) 1 (0.8) 0
Pulmonary embolism 1 (0.8) 1 (0.8) 0

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase.